Lv3
310 积分 2024-09-08 加入
Long-term survival case of SCLC transformation after Osimertinib resistance in EGFR-mutant NSCLC: Benefits from chemo-immunotherapy combined with anti-angiogenic therapy followed by Osimertinib rechallenge
18天前
已完结
EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study
19天前
已完结
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
1个月前
已完结
Multi-cohort analysis reveals altered archaea in colorectal cancer fecal samples across populations
3个月前
已完结
Microbiota-driven antitumour immunity mediated by dendritic cell migration
3个月前
已完结
Osimertinib Retreatment for Patients with Advanced EGFR-mutated Non-Small Cell Lung Cancer
4个月前
已完结
Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses
5个月前
已完结
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
5个月前
已关闭
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
5个月前
已完结
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
6个月前
已完结
皖公网安备34019202002308
